Thermo Fisher Scientific (TMO) is back in focus after unveiling its Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the ASMS 2026 conference, refocusing attention on its high-end analytical instruments portfolio.

The stock has come under pressure in recent months, with the share price down 20.2% year to date and weaker over the past quarter. However, the 1 year total shareholder return of 18.07% remains positive, suggesting recent excitement around new products is meeting more cautious sentiment.

If the Orbitrap announcements have you thinking about where else advanced tools and research platforms could create long term opportunities, it is worth scanning for other ideas through the 39 healthcare AI stocks

With Thermo Fisher now trading 20.2% lower year to date, yet showing a 1 year total return of 18.07% and an indicated 20.24% intrinsic discount, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 22.7% Undervalued

Thermo Fisher Scientific's most followed narrative pegs fair value at $611.56 versus the last close of $472.80, putting a spotlight on the gap between market price and modeled worth.

Strong momentum in high-impact innovation evidenced by next-generation analytical tools such as the Orbitrap mass spectrometers and AI integration into drug development workflows positions Thermo Fisher to capture incremental share as genomics and precision medicine proliferate, structurally supporting future revenues and margins.

Want to see what kind of revenue trajectory and margin uplift that narrative is incorporating, and how those feed into the discount rate and future earnings power assumptions that drive the $611.56 figure?

Result: Fair Value of $611.56 (UNDERVALUED)

However, analysts also flag that prolonged funding pressure in academic and government labs, as well as ongoing China weakness, could undercut the growth and margin path behind that $611.56 figure.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of optimism and concern feels familiar, it is a sign to look under the hood yourself and move quickly to test the story against the data, starting with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with Thermo Fisher, you could miss other compelling setups, so put a few minutes into scanning fresh ideas that match your style and risk comfort.

• Zero in on quality at a discount by checking stocks highlighted in the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies featured in the 9 dividend fortresses.
• Prioritise resilience by filtering for companies in the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.